Lenalidomide-induced cytopenias: Relationship to hematologic improvement in patients with myelodysplastic syndromes (MDS)

被引：2
|
作者：
Sekeres, Mikkael A. [1 ]
Maciejewski, Jwoslaw P. [1 ]
Giagounidis, Aristoteles [2 ]
Wride, Kenton [3 ]
Knight, Robert D. [3 ]
Raza, Azra [4 ]
List, Alan F. [5 ]
机构：
[1] Cleveland Clin Taussig Canc, Cleveland, OH USA
[2] St Johannes Hosp, Duisburg, Germany
[3] Celgene Corp, Summit, NJ USA
[4] Univ Massachusetts, Med Ctr, Worcester, MA 01003 USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.821.821
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
821
引用
收藏
页码：252A / 252A
页数：1
相关论文
共 50 条
  • [31] LENALIDOMIDE TREATMENT IN 20 PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS). MULTICENTER REGISTRY
    Arrizabalaga, B.
    Del Orbe, R.
    Zamora, M.
    Ardanaz, M.
    Arguinano, J.
    Sirvent, M.
    Atucha, L.
    Atucha, J.
    Insunza, A.
    Montes, C.
    Campeny, A.
    HAEMATOLOGICA, 2013, 98 : 585 - 585
  • [32] International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes
    Kao, Jelena M.
    McMillan, Alex
    Greenberg, Peter L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (10) : 765 - 770
  • [33] Evaluating Complete Remission with Incomplete Hematologic Recovery (CRh) As a Response Criterion in Myelodysplastic Syndromes (MDS)
    Brunner, Andrew M.
    Gavralidis, Alexander
    Al Ali, Najla
    Komrokji, Rami S.
    Zeidan, Amer M.
    Sallman, David A.
    BLOOD, 2021, 138
  • [34] Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
    Andrew M. Brunner
    Alexander Gavralidis
    Najla Al Ali
    Anthony Hunter
    Rami Komrokji
    Amer Zeidan
    David A. Sallman
    Blood Cancer Journal, 12
  • [35] Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
    Brunner, Andrew M.
    Gavralidis, Alexander
    Al Ali, Najla
    Hunter, Anthony
    Komrokji, Rami
    Zeidan, Amer
    Sallman, David A.
    BLOOD CANCER JOURNAL, 2022, 12 (11)
  • [36] Model Heterogeneity in Predicting Outcomes of Patients with Myelodysplastic Syndromes (MDS)
    Al-Issa, Karam
    Madanat, Yazan F.
    Mukherjee, Sudipto
    Hirsch, Cassandra M.
    Gerds, Aaron T.
    Abuhadra, Nour
    Makhoul, Ahed
    Awada, Hassan
    Asad, Mohammad Fahad B.
    Goyal, Abhinav
    Advani, Anjali S.
    Kuzmanovic, Teodora
    Przychodzen, Bartlomiej P.
    Carraway, Hetty E.
    Maciejewski, Jaroslaw P.
    Sekeres, Mikkael A.
    Nazha, Aziz
    BLOOD, 2017, 130
  • [37] Characteristics and Outcome Of Myelodysplastic Syndromes (MDS) Patients With Autoimmune Diseases
    Komrokji, Rami S.
    Kulasekararaj, Austin G.
    Al Ali, Najla H.
    Kordasti, Shahram Y.
    Bart-smith, Emily
    Benjamin, Craig
    Padron, Eric
    Zhang, Ling
    Lancet, Jeffrey E.
    List, Alan
    Mufti, Ghulam J.
    Epling-Burnette, Pearlie K.
    BLOOD, 2013, 122 (21)
  • [38] Treatment and outcome of 23 paediatric patients with myelodysplastic syndromes (MDS)
    Polychronopoulou, S
    Panagiotou, JP
    Papadakis, V
    Parcharidou, A
    Psiachou, H
    Mavrou, A
    Haidas, S
    LEUKEMIA, 2000, 14 (05) : 969 - 969
  • [39] Clonal Heterogeneity in Patients with Myelodysplastic Syndromes (MDS) and Complex Karyotypes
    Zemanova, Zuzana
    Michalova, Kyra
    Brezinova, Jana
    Lhotska, Halka
    Svobodova, Karla
    Sarova, Iveta
    Lizcova, Libuse
    Izakova, Silvia
    Ransdorfova, Sarka
    Krejcik, Zdenek
    Belickova, Monika
    Siskova, Magda
    Jonasova, Anna
    Neuwirtova, Radana
    Zmolikova, Jana
    Cermak, Jaroslav
    BLOOD, 2014, 124 (21)
  • [40] Phase II study of amifostine in patients with myelodysplastic syndromes (MDS).
    List, AF
    Holmes, H
    Greenberg, PL
    Bennett, JM
    Oster, W
    BLOOD, 1999, 94 (10) : 305A - 305A
12345